AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Chemed Corp Q2 2025 Earnings Call Highlights: Navigating Challenges and Strategic Growth
ByAinvest
Thursday, Jul 31, 2025 3:23 am ET1min read
Chemed Corp reported Q2 2025 net revenue of $396.2 million for VITAS, a 5.8% increase YoY. Roto-Rooter revenue increased 0.6% YoY. Adjusted EBITDA for VITAS was flat at $66.8 million, while Roto-Rooter's decreased 18.7% to $48.6 million. The company revised its full-year 2025 earnings per diluted share guidance to $22-$22.30, down from $24.95-$25.45.
Chemed Corporation reported mixed performance for the second quarter of 2025, with earnings per share (EPS) of $4.27 falling short of expectations and revenue coming in below projections. The company's stock price dropped 8.8% in after-hours trading, closing at $430.20.Key Takeaways:
- EPS: $4.27 (missed forecast of $5.39)
- Revenue: $618.8 million (below forecast of $650.6 million)
- Stock price: Down 8.8% to $430.20
Chemed's VITAS division, which provides hospice care, saw a 5.8% increase in net revenue year-over-year to $396.2 million. However, Roto Rooter, the company's plumbing and drain cleaning division, experienced a significant 18.7% decline in adjusted EBITDA to $48.6 million.
The company revised its full-year 2025 EPS guidance downward to $22.00-$22.30 from $24.95-$25.45. Despite the earnings miss, Chemed's stock appears undervalued, with management actively buying back shares to support shareholder value.
Market Reaction:
Following the earnings announcement, Chemed's stock price dropped 8.8%, reflecting investor disappointment. The stock fell to $430.20, moving closer to its 52-week low of $410. This decline contrasts with broader market trends, where many healthcare stocks have remained stable.
Outlook:
Chemed anticipates improved performance in the latter half of the year, with VITAS revenue expected to increase by 7.5%-8.5% and Roto Rooter projecting a 1.25%-1.75% revenue increase. The company maintains a strong financial health score of 3.05 out of 5, with robust cash flows sufficient to cover interest payments and a conservative debt-to-equity ratio of 0.12.
References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-chemed-misses-q2-2025-estimates-shares-drop-93CH-4160806
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet